Keywords:
хронический вирусный гепатит В (HBV), хронический вирусный гепатит С (HCV), хронический вирусный гепатит D (HDV), вирусный цирроз печени, гепатоцеллюлярная карцинома (GTSK), альфа-фетопротеин (AFP).References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med. 2019;17(1):74. doi:10.1186/s12967-019-1828-0
Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28(16):3537–3545. doi:10.1158/1078-0432.CCR-21-3275
Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2020;26(18):4795–4804. doi:10.1158/1078-0432.Ccr-19-3884
Saeki I, Yamasaki T, Yamashita S, et al. Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment. Cancers. 2020;12(4): 779. doi: 10. 3390/cancers12040779
Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28(16):3537–3545. doi:10.1158/1078-0432.CCR-21-3275
Sun XQ, Mei J, Lin WP, et al. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer. 2021;21(1):775. doi:10.1186/s12885-021-08428-w
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
Hu X, Chen R, Wei Q, Xu X. The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we? Int J Biol Sci. 2022;18(2):536–551. doi:10.7150/ijbs.64537
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
C.W. Su, K.C. Fang, R.C. Lee, C.A. Liu, P.H. Chen, P.C. Lee, et al.
Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: a propensity score matching analysis J Formos Med Assoc, 119 (2) (2020), pp. 610-620
Y. Chang, C.Y. Wei, P.H. Chen, M.C. Hou, Y. Chao, G.Y. Chau, et al. The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma J Chin Med Assoc, 84 (2) (2021), pp. 136-143. C.E. Costentin, R. Layese, V. Bourcier, C. Cagnot, P. Marcellin, D. Guyader, et al.
Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. - Gastroenterology, 155 (2) (2018), pp. 431-442 e410.
S. Gupta, S. Bent, J. Kohlwes Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysi Ann Intern Med, 139 (1) (2003).- Р. 46-50. 17.J.A. Marrero, L.M. Kulik, C.B. Sirlin, A.X. Zhu, R.S. Finn, M.M. Abecassis, et al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases Hepatology, 68 (2) (2018), pp. 723-750
W.Y. Kao, Y.Y. Chiou, H.H. Hung, C.W. Su, Y.H. Chou, J.C. Wu, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy Clin Radiol, 67 (5) (2012), pp. 429-43
C.W. Su, K.C. Fang, R.C. Lee, C.A. Liu, P.H. Chen, P.C. Lee, et al. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: a propensity score matching analysis
J Formos Med Assoc, 119 (2) (2020), pp. 610-620J.C. Nault, A. Villanueva Biomarkers for heaptobiliary cancers Hepatology, 73 (Suppl 1) (20 21), pp. 115-127